Zachary Roberts - 25 Jan 2024 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
EVP of R&D
Signature
/s/Earl Douglas, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
25 Jan 2024
Net transactions value
$0
Form type
4
Filing time
31 Jan 2024, 17:45:39 UTC
Previous filing
24 Jan 2024
Next filing
23 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +140,000 +37% $0.000000 515,253 25 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to buy) Award $0 +494,949 $0.000000 494,949 25 Jan 2024 Common Stock 494,949 $3.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter.